Control compounds for preclinical drug-induced liver injury assessment : consensus-driven systematic review by the ProEuroDILI network

Segovia-Zafra, Antonio (author), Godec, Sergej (author), Milisav, Irina (author), Lucena, M. Isabel (author), Fernández-Checa, José C (author)

Background & aims: Idiosyncratic drug-induced liver injury (DILI) is a complex and unpredictable event caused by drugs, and herbal or dietary supplements. Early identification of human hepatotoxicity at preclinical stages remains a major challenge, in which the selection of validated in vitro systems and test drugs has a significant impact. In this systematic review, we analyzed the compounds used in hepatotoxicity assays and established a list of DILI-positive and -negative control drugs for validation of in vitro models of DILI, supported by literature and clinical evidence and endorsed by an expert committee from the COST Action ProEuroDILI Network (CA17112). Methods: Following 2020 PRISMA guidelines, original research articles focusing on DILI which used in vitro human models and performed at least one hepatotoxicity assay with positive and negative control compounds, were included. Bias of the studies was assessed by a modified 'Toxicological Data Reliability Assessment Tool'. Results: A total of 51 studies (out of 2,936) met the inclusion criteria, with 30 categorized as reliable without restrictions. Although there was a broad consensus on positive compounds, the selection of negative compounds lacked clarity. 2D monoculture, short exposure times and cytotoxicity endpoints were the most tested, although there was no consensus on drug concentrations. Conclusions: Extensive analysis highlighted the lack of agreement on control compounds for in vitro DILI assessment. Following comprehensive in vitro and clinical data analysis together with input from the expert committee, an evidence-based consensus-driven list of 10 positive and negative control drugs for validation of in vitro models of DILI is proposed. Impact and implications: Prediction of human toxicity early in the drug development process remains a major challenge, necessitating the development of more physiologically relevant liver models and careful selection of drug-induced liver injury (DILI)-positive and -negative control drugs to better predict the risk of DILI associated with new drug candidates. Thus, this systematic study has crucial implications for standardizing the validation of new in vitro models of DILI. By establishing a consensus-driven list of positive and negative control drugs, the study provides a scientifically justified framework for enhancing the consistency of preclinical testing, thereby addressing a significant challenge in early hepatotoxicity identification. Practically, these findings can guide researchers in evaluating safety profiles of new drugs, refining in vitro models, and informing regulatory agencies on potential improvements to regulatory guidelines, ensuring a more systematic and efficient approach to drug safety assessment.

• Language: English
• Keywords: clinical data, control compounds, drug-induced liver injury, expert committee, panel of control drugs, preclinical drug safety testing, validation of in vitro DILI models
• Work type: Article
• Typology: 1.01 - Original Scientific Article
• Organization: MF - Faculty of Medicine
• Publication status: Published
• Publication version: Version of Record
• Year: 2024
• Number of pages: Str. 630-640
• Numbering: Vol. 81, iss. 4
• PID: 20.500.12556/RUL-182419
• UDC: 615.2:615.9
• ISSN on article: 0168-8278
• DOI: 10.1016/j.jhep.2024.04.026
• COBISS.SI-ID: 197028867
• Publication date in RUL: 11.05.2026

Record is a part of a journal

• Title: Journal of hepatology
• Shortened title: J. hepatol.
• Publisher: Elsevier
• ISSN: 0168-8278
• COBISS.SI-ID: 62487

Licences

• License: CC BY-ND 4.0, Creative Commons Attribution-NoDerivatives 4.0 International
• Link: http://creativecommons.org/licenses/by-nd/4.0/
• Description: Under the NoDerivatives Creative Commons license one can take a work released under this license and re-distribute it, but it cannot be shared with others in adapted form, and credit must be provided to the author.

Secondary language

• Language: Slovenian
• Keywords: klinični podatki, kontrolne spojine, z zdravili povzročena poškodba jeter, strokovna komisija, panel nadzornih zdravil, predklinično testiranje varnosti zdravil, validacija in vitro modelov DILI